Lung AI vs Vivid T9/Vivid T8

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Lung AI

by Exo

Vivid T9/Vivid T8

by GE HealthCare

AI Verdict

These tools are adjacent competitors, both offering AI-powered ultrasound systems for cardiology and imaging. Tool A (Lung AI) focuses on a handheld, on-device solution with specific AI for lung and cardiac conditions, ideal for portable, real-time decision-making. Tool B (Vivid T9/T8) provides advanced, on-premise cardiovascular ultrasound systems with a strong emphasis on comprehensive cardiac measurements and workflow efficiency.

Choose Lung AI if…

Choose Lung AI if you require a highly portable, handheld ultrasound solution for rapid, on-the-spot assessments in emergency medicine or critical care settings. Its on-device AI capabilities for lung conditions like pleural effusion and consolidation, along with cardiac indicators, make it ideal for quick decision-making without needing internet connectivity.

View Lung AI →

Choose Vivid T9/Vivid T8 if…

Choose GE HealthCare's Vivid T9/T8 if your primary need is a comprehensive, high-performance cardiovascular ultrasound system for detailed diagnostics in cardiology, critical care, or radiology departments. Its advanced AI-powered tools for automated cardiac measurements (e.g., AutoEF, AFI) and workflow optimization are designed for in-depth analysis and seamless integration into a hospital's existing imaging infrastructure.

View Vivid T9/Vivid T8 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Lung AI	Vivid T9/Vivid T8
Pricing	Contact for pricing	Contact for pricing
Deployment	On-device (integrated with Exo Iris handheld ultrasound device)	On-premise hardware
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	1 AI-estimated	1 AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool A is a handheld, easy-to-use ultrasound platform with on-device AI and guided image capture, making it highly portable and accessible for point-of-care scenarios. Its focus on intuitive operation and AI-powered POCUS education enhances its usability for a broader range of clinicians.

Clinical Value

Vivid T9/Vivid T8

Tool B offers a more comprehensive and advanced suite of AI-powered tools for detailed cardiovascular assessment, including automated ejection fraction, myocardial strain analysis, and advanced Doppler measurements. Its 'Shared Services' capabilities also suggest broader diagnostic utility beyond just cardiac applications.

Pricing & Value

Vivid T9/Vivid T8

While both tools require contacting the vendor for pricing, Tool B provides a starting price point for one of its models (Vivid T8 around $22,800), offering a slightly higher degree of pricing transparency than Tool A, which gives no indication.

Enterprise Readiness

Lung AI

Tool A explicitly details comprehensive enterprise features including DICOM, PACS/VNA, and Worklist integration, as well as Enterprise EHR integration, order/encounter-based workflows, and automated billing. This demonstrates a robust capability for integration into complex healthcare IT environments.

Innovation

Lung AI

Tool A represents a more innovative approach with its high-performance, handheld ultrasound platform featuring on-device AI processing and AI-powered POCUS education. This form factor and integrated intelligence for point-of-care are more disruptive than enhancing traditional cart-based systems.

Support & Docs

Vivid T9/Vivid T8

GE HealthCare offers extensive support for Tool B, including unlimited remote support via Expert Live Support and a standard 3-year service coverage with on-site and remote assistance. They also provide comprehensive manuals and dedicated support channels.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Lung AI	Vivid T9/Vivid T8
Company	Exo	GE HealthCare
Primary Specialties	Cardiology, Emergency Medicine, Pulmonology	Cardiology, Critical Care, Radiology
Key AI for Cardiac Assessment	Automated AI-based indicators for cardiac conditions (e.g., heart failure, hypertrophy)	AI-based Cardiac Auto Doppler for automated measurements, AutoEF (Automated Ejection Fraction) for left ventricular function assessment, Automated Function Imaging (AFI) for myocardial strain and wall motion analysis
Key AI for Lung Assessment	AI-powered detection of pleural effusion, AI-powered detection of consolidation/atelectasis	Not specified
Form Factor	Handheld ultrasound platform	Advanced cardiovascular ultrasound systems
AI Processing Location	On-device AI processing (operates without internet)	Not specified

Videos

Demos, reviews, and walkthroughs featuring Lung AI and Vivid T9/Vivid T8.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for point-of-care versus dedicated imaging departments, and what are their respective audit trail capabilities?

Tool A (Exo Lung AI), being a handheld device with on-device AI, is designed for rapid point-of-care assessments in diverse settings like emergency departments or clinics, enabling immediate decision-making. Tool B (GE HealthCare Vivid T9/T8), as a cart-based system, is better suited for comprehensive diagnostic exams in cardiology labs, critical care units, or radiology departments, supporting more in-depth analysis and standardized procedures. Tool B offers DICOM connectivity for seamless integration of images and data into PACS and EHR systems, which typically includes robust audit trails for data access and modifications. For Tool A, while it processes AI on-device, the method for transferring images and AI findings to the EHR and its specific audit trail functionalities would need to be clarified, especially given its offline operational capability.

What specific clinical conditions do the AI features of each tool primarily target, and how do they contribute to diagnostic accuracy?

Tool A's AI focuses on detecting specific lung pathologies like pleural effusion and consolidation/atelectasis, and provides indicators for cardiac conditions such as heart failure and hypertrophy, aiding in rapid point-of-care diagnosis. Clinical studies have shown that AI assistance with Tool A improves accuracy in lung ultrasound interpretation, increasing sensitivity for pleural effusion detection by 18% and for consolidation/atelectasis by 16%. Tool B's AI suite, including Cardiac Auto Doppler, AutoEF, and Automated Function Imaging (AFI), is designed to enhance the accuracy and efficiency of comprehensive cardiovascular assessments, providing detailed measurements of left ventricular function and myocardial strain.

What is the expected learning curve for physicians new to these AI ultrasound systems, and how quickly can a practice expect to realize clinical value?

Tool A, with its 'easy-to-use' design, guided image capture, and integrated POCUS education (Exo U), likely offers a shorter learning curve, allowing physicians to quickly integrate it into their practice for rapid diagnostic insights and realize value sooner. Tool B, while an advanced system, includes features like Scan Assist Pro designed to optimize workflow and standardize exams, which can help experienced users enhance efficiency and achieve clinical value through more consistent and comprehensive diagnostics.

What are the key considerations for deploying these ultrasound systems across multiple clinical sites or a larger healthcare network?

For Tool A, its handheld design and on-device AI processing make multi-site rollout relatively straightforward, primarily involving device distribution and user training, as it operates independently of network infrastructure for AI functions. Tool B, being an on-premise hardware system, would require more extensive planning for multi-site deployment, including physical installation, network integration via DICOM standards, and IT support at each location.

In which specific clinical scenarios would each tool demonstrate its greatest utility for a physician, considering their distinct capabilities?

Tool A, with its handheld design and AI for lung and basic cardiac assessments, is highly valuable in emergency medicine for rapid triage, in pulmonology for bedside evaluations, and in critical care for quick monitoring of conditions like pulmonary edema or heart failure. Tool B, with its advanced cardiac AI features like AutoEF and AFI, and shared services capabilities, excels in dedicated cardiology labs for comprehensive diagnostics, in critical care for detailed hemodynamic assessments, and in radiology for broader ultrasound applications requiring high image quality and advanced measurements.